RxDoctor Payments Data

Andrea Robbins

Primary Care · Gilbert, AZNPI 1902446370

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 49.3% of the total. Reporting peaked in 2021 at $907 and has fallen 79.1% since, to $190 in 2025.

$1,733in general payments, 2019–2025

Across 24 payments — averaging $72.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$855
  • Novo Nordisk$252
  • Nevro Corp.$163
  • Astellas Pharma US Inc$124
  • Axsome Therapeutics, Inc.$122
  • AbbVie$120
  • plus $98 from 3 others

What the payments were for

  • Consulting fees$80046%
  • Travel & lodging$221%
  • Food & beverage$81147%
  • Education$1006%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,733 in reported general payments places this provider in the 75th percentile of 151 primary care providers in Arizona.

See all primary care providers in Arizona

Medicare billing

Part B allowed, 2024
$14,410
Medicare patients
61
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide11$34,060
MounjaroTirzepatide19$19,962
OzempicSemaglutide18$18,841
LinzessLinaclotide11$6,107
TrintellixVortioxetine Hydrobromide17$5,778
Duloxetine Hcl14$541
Pregabalin18$508
Valsartan11$462
Albuterol Sulfate HfaAlbuterol Sulfate12$457
Levothyroxine Sodium58$351
Atorvastatin Calcium40$306
Escitalopram Oxalate21$286
Amitriptyline Hcl15$235
Omeprazole25$223
Buspirone Hcl25$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$58$19,96219 claims
Novo NordiskOzempic$252$18,84118 claims
AbbVieLinzess$120$6,10711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 151 primary care providers in Arizona.

Other primary care in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →